These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9832706)

  • 1. Surgical implications of platelet glycoprotein IIb-IIIa inhibition.
    Duke C; Grammie JS
    J Thorac Cardiovasc Surg; 1998 Dec; 116(6):1083-4. PubMed ID: 9832706
    [No Abstract]   [Full Text] [Related]  

  • 2. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
    Aylward P
    Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944
    [No Abstract]   [Full Text] [Related]  

  • 3. Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator.
    Steinhubl SR; Moore SA; Lincoff AM
    J Thorac Cardiovasc Surg; 2000 Feb; 119(2):401-2. PubMed ID: 10649221
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists.
    Stiegler HM; Fischer Y; Steiner S
    Lancet; 1999 Apr; 353(9159):1185. PubMed ID: 10210005
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.
    Ali A; Patil S; Grady KJ; Schreiber TL
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):181-4. PubMed ID: 10642769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor.
    Sitges M; Villa FP
    Int J Cardiol; 1997 Dec; 62(3):269-71. PubMed ID: 9476687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
    Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 13. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties.
    Peter K; Schwarz M; Bode C
    Circulation; 2002 May; 105(21):E180-1. PubMed ID: 12034670
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?
    Kereiakes DJ
    Am Heart J; 1999 Jul; 138(1 Pt 2):S39-46. PubMed ID: 10385790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
    J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myocardial revascularization after pretreatment with the GPIIb/IIIa receptor blocker abciximab].
    Vahl CF; Kayhan N; Thomas G; Bode C; Hagl S
    Z Kardiol; 2001 Dec; 90(12):889-97. PubMed ID: 11826830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abciximab (ReoPro) removal with a hemoconcentrator during cardiopulmonary bypass.
    Lemmer JH
    J Thorac Cardiovasc Surg; 1999 Nov; 118(5):980-1. PubMed ID: 10534719
    [No Abstract]   [Full Text] [Related]  

  • 18. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.